SPRO— AI Stock Forecast & Price Targets
Published 7/17/2026 · A free sample of K3vl4r’s AI-powered analysis.
Kronos price forecasts, scored fundamentals & technicals, and a multi-horizon plan.
View the live SPRO price forecast →
SPRO is a $91M micro-cap that has rejected every positive catalyst brutally, with price collapsing ~40% MTD despite a transformative $105M non-dilutive KKR royalty deal and an Innovent SP001/CD40L in-license worth up to $1.1B. The tape (RSI 25.8, -34.8% vs SMA200, below all moving averages) and structural revenue collapse (Q1'26 revenue $258K, -95% Q/Q) argue for continued distribution, but a clean balance sheet ($56M cash, 0.05 debt/equity) and August 11 earnings within 25 days create binary optionality. HOLD with a bearish lean into the print — model forecasts remain unreliable (sub-baseline directional accuracy) and prior base targets have systematically failed to print.
1-4 week view: HOLD/AVOID new entries. Earnings on August 11 (~25 days) is a binary event — do not size a swing into it. If long, tolerate the position but do not average down above $1.55; hard invalidation is a weekly close below $1.50 (breaks the 52W low). Bounce sellers can fade $1.70-$1.75 resistance for a $1.55 retest. Sizing: quarter-position max for any speculative long here; the tape's rejection of good news is the dominant signal.
1-6 month view: The path to $2.00-$2.20 requires (a) August 11 print showing cash-burn discipline and a credible SP001 Phase 2 initiation timeline, (b) Utebzi royalty run-rate confirmation validating KKR facility coverage, and (c) absence of any CD40L class safety signal. Expected return range: -25% to +40% (wide because binary). Base case is a $1.70-$1.90 grind if the print is uneventful. What flips me constructive: a green weekly close above $1.85 on volume post-earnings AND a clean safety readout. What flips me bearish: a dilutive raise announcement or SP001 initiation delay beyond Q4.
1-3 year view: This is a lottery ticket on SP001 in IgG4-related disease succeeding through Phase 2 into pivotal — if it works, the ex-China rights on a $1B+ addressable indication supports a multi-hundred-million-dollar valuation off the current $91M cap. If SP001 fails, SPRO becomes a Utebzi royalty stream shell worth roughly the royalty NPV net of obligations, likely $0.75-$1.25. The biggest structural risk is the CD40L class safety history (thromboembolism has killed prior programs) — this is genuinely a coin-flip clinical bet, not a value trade. Micro-cap illiquidity and reliance on lumpy milestone recognition rather than recurring revenue make this untenable as a core holding.
The fundamental picture is bifurcated between headline TTM optics and underlying operating reality. TTM revenue of $61.2M and profit margin of 24.9% look attractive with P/E of 6.44 and EV/Sales of 0.68, but these are milestone artifacts — Q4'25 booked $39.7M of lumpy revenue and $31.5M net income from a one-time recognition event, while Q1'26 revenue collapsed to $258K (-95% Q/Q) with a -$7.5M operating loss. Balance sheet remains the saving grace: $56.1M cash, only $2.5M debt, current ratio 10.5, working capital $52.1M, and the fresh $105M KKR non-dilutive royalty facility extends runway meaningfully without shareholder dilution. However, the Innovent SP001 deal carries undisclosed upfront and milestone payment obligations that could pressure the cash position. Free cash flow of $15.9M in Q1'26 is misleading because it reflects working capital timing from Q4 milestone collections, not sustainable operations. Insider ownership at 26% is a positive alignment signal; institutional ownership at just 14.6% suggests the story hasn't attracted quality capital.
Technicals are unambiguously broken across every timeframe. The 1h chart shows a stair-step decline from ~$2.30 in late June to $1.54 with a fresh capitulation leg below $1.70 support. The 4h chart shows the breakdown from the $2.15-$3.00 April-June range, with $1.54 now testing the 52-week low of $1.515. The weekly chart shows the stock has round-tripped a January $19 spike to sit near all-time lows. Price sits -25% below SMA20, -36% below SMA50, and -35% below SMA200 — all three trend proxies pointing down with widening dispersion. RSI at 25.8 is oversold but not extreme for this name; short float has climbed from 4.3% to 6.7% in 45 days confirming bearish conviction. The model's forecast bands (Kronos AI) project $2.17-$2.67 mean reversion, but with 1d directional accuracy at 59% vs 82% naive baseline and 1wk at 83% vs 100% naive baseline, the model is beaten by trend-persistence in this regime — the bullish forecast should be heavily discounted. Key support: $1.515 (52W low), then psychological $1.50. Resistance: $1.70 (recent gap), then $2.00.
The news flow is genuinely transformative but the tape refuses to price it. On July 14, three material 8-K items landed simultaneously: (1) exclusive ex-China license to Innovent's IBI355/SP001 CD40L antibody with up to $1.1B in milestone potential, (2) $105M non-recourse royalty financing from HealthCare Royalty (KKR-owned) monetizing future Utebzi/tebipenem royalties, and (3) a strategic pivot toward immunology. A sell-side note framed this as a 'Buy on Utebzi royalty deal.' In a normal tape this is a re-rating catalyst; instead SPRO gave back another 7.6% since the announcement and short interest expanded. The signal here is clear: the market is either (a) discounting SP001 clinical risk (CD40L class carries thromboembolism history), (b) worried about the undisclosed Innovent upfront/milestone cash outflow, or (c) exhausted holder-base capitulation regardless of fundamentals. Historically on this name, positive catalysts have been distribution events not accumulation events — a pattern that must be respected.
- SP001/IBI355 Phase 2 initiation in IgG4-related disease — key value inflection with up to $1.1B in milestones from Innovent deal
- Utebzi (tebipenem) commercial launch royalties via GSK partnership, monetized upfront through $105M KKR non-dilutive facility
- SPR206 partnership economics with Everest Medicines in Greater China/Southeast Asia — smaller but pipeline-diversifying MDR asset
- Immunology platform expansion off the CD40L in-license, positioning as a clinical-stage immunology story vs prior antibiotic pure-play
- August 11 earnings could reset the narrative if Q2 shows cash-burn discipline and clear SP001 development milestones
- CD40L class thromboembolism safety signal in SP001 Phase 2 — historically terminal for programs in this class
- Undisclosed Innovent upfront and milestone cash obligations could erode the $56M cash cushion faster than the KKR facility offsets
- Structural revenue collapse to $258K in Q1'26 (-95% Q/Q) confirms no sustainable operations — reliant on lumpy milestone recognition
- Tape pattern: positive news catalysts consistently trigger distribution not accumulation on this name — market skepticism is entrenched
- Short float climbed from 4.3% to 6.7% in 45 days signals institutional bearish conviction despite the transformative deals
- Micro-cap illiquidity ($91M cap, 1.18M avg volume) amplifies drawdowns and makes exit optionality poor
- August 11 earnings is a binary event — gap risk in either direction with IV crush penalizing option holders
- Model forecast unreliable in this regime (59% directional accuracy vs 82% naive baseline) — cannot lean on bullish AI mean-reversion projection
Get AI analysis on any stock
This is one of hundreds of Kronos AI reports — scored fundamentals & technicals, bull/base/bear price targets, a multi-horizon plan, and continuously-updated forecasts across the market. Create a free account to explore them all.
Create your free account →Already a member? Sign in · Join our Discord